Stock comparison
Telix Pharmaceuticals Limited
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
TLX
Telix Pharmaceuticals Limited
Market cap
$3.21B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | TLX | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 31F | 71B | UTHR |
| Benjamin Graham | 49D | 76B | UTHR |
| Philip Fisher | 50C | 76B | UTHR |
| Peter Lynch | 29F | 62C | UTHR |
| Joel Greenblatt | 0F | 46D | UTHR |
| Charlie Munger | 44D | 64C | UTHR |
| Terry Smith | 38D | 64C | UTHR |
Side-by-side metrics
| Metric | TLX | UTHR |
|---|---|---|
| Market cap | $3.21B | $24.13B |
| P/E (TTM) | - | 19.2x |
| EV/EBIT | 211.6x | 15.2x |
| ROIC (TTM) | 1.77% | 18.81% |
| Gross margin | 50.76% | 86.58% |
| Net margin | -0.89% | 40.61% |
| Revenue CAGR 5y | 2.55% | 17.22% |
| EPS CAGR 5y | - | 29.84% |
| Debt / Equity | 1.3x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
TLX leads on
- P/E (TTM)-vs 19.2x+104%
- Revenue CAGR 5y2.55%vs 17.22%+93%
UTHR leads on
- Net margin40.61%vs -0.89%+102%
- Debt / Equity-vs 1.3x+100%
- EV/EBIT15.2xvs 211.6x+93%
- ROIC (TTM)18.81%vs 1.77%+91%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.